The company reported a net loss of $4.4 million, or $0.07 per share, compared with net income of $1.9 million, or $0.03 per share, a year earlier. Management said net operating cash burn was about $200,000 excluding those payments and reiterated its expectation to reach operating cash flow breakeven in the second half of 2026. Cytosorbents has a pre-submission meeting scheduled with the FDA later in August to discuss additional mechanistic data. Looking ahead, management identified four value drivers: reaching operating cash flow breakeven, restoring CytoSorb revenue growth, pursuing U.S. approval for DrugSorb-ATR and unlocking strategic value from HemoDefend-BGA. About Cytosorbents (NASDAQ:CTSO)Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification.